Drug news
ETC 1002 (Esperion Therapeutics) positive in Phase II trial for Dyslipidaemia
Esperion Therapeutics, has announced positive results from a Phase II clinical trial for ETC-1002. This novel small molecule activator of AMP Kinase has demonstrated preclinical and clinical activity as a metabolic regulator of imbalances in lipid and carbohydrate metabolism. Results were presented in an oral presentation at the 2012 American College of Cardiology meeting in Chicago.